CPC C12Q 1/6874 (2013.01) [C12Q 1/6851 (2013.01); C12Q 1/6876 (2013.01); G01N 33/6818 (2013.01); A61K 38/00 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] | 10 Claims |
1. A method of treating a subject with a therapeutic agent that treats or inhibits hearing loss, wherein the subject has hearing loss, the method comprising the steps of:
determining whether the subject has a Kelch Domain Containing 7B (KLHDC7B) missense variant nucleic acid molecule encoding a KLHDC7B predicted loss-of-function polypeptide by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the KLHDC7B missense variant nucleic acid molecule encoding the KLHDC7B predicted loss-of-function polypeptide; and
administering or continuing to administer the therapeutic agent that treats or inhibits hearing loss in a standard dosage amount to a subject that is KLHDC7B reference; and
administering or continuing to administer the therapeutic agent that treats or inhibits hearing loss in an amount that is the same as or greater than a standard dosage amount to a subject that is heterozygous or homozygous for the KLHDC7B missense variant nucleic acid molecule;
wherein the presence of a genotype having the KLHDC7B missense variant nucleic acid molecule encoding the KLHDC7B predicted loss-of-function polypeptide indicates the subject has an increased risk of developing hearing loss, wherein the KLHDC7B missense variant nucleic acid molecule encodes KLHDC7B K181fs or KLHDC7B G302fs.
|